Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 651-658

  Liao, Z J ^a,b   Guo, Y H ^a   Zhao, Z ^a   Yao, J T ^a   Xu, R ^a   Nan, K J ^b  

^a Tumor Hospital of Shannxi Province   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Circulating tumor cell; EpCAM; Gemcitabine; HGF cMET pathway; Non small cell lung cancer

Indexed keywords

BETA ACTIN; CYTOKERATIN 18; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VASCULOTROPIN; ANTINEOPLASTIC ANTIMETABOLITE; CELL ADHESION MOLECULE; DEOXYCYTIDINE; EPCAM PROTEIN, HUMAN; SCATTER FACTOR; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CELL MIGRATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MICROMETASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; NEOPLASM MICROMETASTASIS; PATHOLOGY; PILOT STUDY; TUMOR CELL LINE; TUMOR EMBOLISM;

AGED; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DEOXYCYTIDINE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM MICROMETASTASIS; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84902603256     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2464     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Ni X, Zhuo M, Su Z, et al: Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA 110: 21083-21088, 2013.
3. Plaks V, Koopman CD and Werb Z: Cancer. Circulating tumor cells. Science 341: 1186-1188, 2013.
4. Li P, Stratton ZS, Dao M, Ritz J and Huang TJ: Probing circulating tumor cells in microfluidics. Lab Chip 13: 602-609, 2013.
5. Young R, Pailler E, Billiot F, et al: Circulating tumor cells in lung cancer. Acta Cytol 56: 655-660, 2012.
6. Liu Y, Qian J, Feng JG, et al: Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases. Cell Oncol (Dordr) 36: 43-53, 2013.
7. Hou HW, Warkiani ME, Khoo BL, et al: Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 3: 1259, 2013.
8. Huang SB, Wu MH, Lin YH, et al: High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab Chip 13: 1371-1383, 2013.
9. Diamond E, Lee GY, Akhtar NH, et al: Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2: 131, 2012.
10. Dong Y, Skelley AM, Merdek KD, et al: Microfluidics and circulating tumor cells. J Mol Diagn 15: 149-157, 2013.
11. Green TL, Cruse JM and Lewis RE: Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol 95: 174-179, 2013.
12. Lin HK, Zheng S, Williams AJ, et al: Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16: 5011-5018, 2010.
13. Alunni-Fabbroni M and Sandri MT: Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods 50: 289-297, 2010.
14. Ross JS and Slodkowska EA: Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 132: 237-245, 2009.
15. Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D and Jirillo A: Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 76: 375-386, 2009.
16. Wen CY, Wu LL, Zhang ZL, et al: Quick-response magnetic nanospheres for rapid, efficient capture and sensitive detection of circulating tumor cells. ACS Nano 8: 941-949, 2014.
17. Chen Q, Ge F, Cui W, et al: Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta 419: 57-61, 2013.
18. Pantel K and Alix-Panabieres C: Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16: 398-406, 2010.
19. Sieuwerts AM, Kraan J, Bolt J, et al: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101: 61-66, 2009.
20. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
21. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
22. Hugo H, Ackland ML, Blick T, et al: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383, 2007. (Pubitemid 47509716)
23. Chaffer CL, Thompson EW and Williams ED: Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185: 7-19, 2007. (Pubitemid 46956838)
24. Vincan E and Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 25: 657-663, 2008.
25. Zavadil J: New TGF-beta and Ras crosstalk in EMT. Cell Cycle 8: 184, 2009.
26. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746, 2003.
27. Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51, 2007.
28. Akhurst RJ, Fitzpatrick DR, Fowlis DJ, Gatherer D, Millan FA and Slager H: The role of TGF-beta s in mammalian development and neoplasia. Mol Reprod Dev 32: 127-135, 1992.
29. Zhou HY, Pon YL and Wong AS: HGF/MET signaling in ovarian cancer. Curr Mol Med 8: 469-480, 2008.
30. Gesto DS, Cerqueira NM, Fernandes PA and Ramos MJ: Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem 19: 1076-1087, 2012.
31. Muggia F, Diaz I and Peters GJ: Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. Expert Opin Investig Drugs 21: 403-408, 2012.
32. Cok G, Goksel T, Soyer S and Aysan T: Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer. Tuberk Toraks 56: 74-80, 2008.
33. Noble S and Goa KL: Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54: 447-472, 1997. (Pubitemid 27395596)
34. Galsky MD, Hahn NM, Powles T, et al: Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11: 175-181, 2013.
35. Martin M, Ruiz A, Munoz M, et al: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8: 219-225, 2007. (Pubitemid 46291704)
36. Reaume MN, Leighl NB, Mittmann N, et al: Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Lung Cancer 82: 115-120, 2013.
37. Gridelli C, Gallo C, Shepherd FA, et al: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3025-3034, 2003. (Pubitemid 46606281)
38. Perlikos F, Harrington KJ and Syrigos KN: Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol 87: 1-11, 2013.
39. Stott SL, Lee RJ, Nagrath S, et al: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2: 25ra23, 2010.
40. Wallwiener M, Hartkopf AD, Baccelli I, et al: The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 137: 503-510, 2013.
41. Ma J, Lin JY, Alloo A, et al: Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402: 711-717, 2010.